A Study to Assess Safety and Efficacy of ASP015K in Participants with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Trial Identifier: 015K-CL-CNA3
Sponsor: Astellas Pharma China, Inc.
Start Date: September 2018
Primary Completion Date: April 2021
Study Completion Date: November 2021
Condition: Rheumatoid Arthritis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Anhui, China
China Beijing, China
China Bengbu, China
China Changchun, China
China Changsha, China
China Chenzhou, China
China Guangdong, China
China Guangzhou, China
China Inner Mongolia, China
China Jieyang, China
China Jilin, China
China Jining, China
China Jiujiang, China
China Kunming, China
China Nanjing, China
China Ningbo, China
China Pingxiang, China
China Qingdao, China
China Shanghai, China
China Shantou, China
China Sichuan, China
China Tianjin, China
China Wuhan, China
China Xining, China
China Xuzhou, China
China Zhengzhou, China
China Zhuzhou, China
Korea (Republic of) Gwangju, Korea (Republic of)
Korea (Republic of) Incheon, Korea (Republic of)
Korea (Republic of) Seoul, Korea (Republic of)
Taiwan, Province of China Taichung, Taiwan, Province of China
Taiwan, Province of China Taipei, Taiwan, Province of China